PHOENIX ― Gastrointestinal cancers are some of the most commonly diagnosed cancers, and they continue to be associated with poor survival outcomes. The drug adagrasib specifically targets the KRASG12C gene mutation that is common in gastrointestinal cancers and inhibits gastrointestinal function.
Trending
- Just like Uber and Netflix, Salvo is bringing on-demand care to GI
- Da Vinci Code: First Autonomous Robot Surgery Achieved in Pig Cadavers (Inside Precision Medicine)
- Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients (CLP)
- Physician Services Top $1 Trillion as ASC-Linked Spending Grows (ASC News)
- AGA members push states to provide obesity care (AGA)
- Vibrant Wellness Launches Redesigned Gut Microbiome Test With Broader Microbial and Metabolic Insights (ACCESS Newswire)
- Oral Semaglutide: By Year’s End, a GLP-1 Weight-Loss Pill? (Medscape)
- Bringing Clinical Trial Enrollment to the Point of Diagnosis (Pharma’s Almanac)